


## AMENDMENTS TO THE CLAIMS

This Listing of the Claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims

1. (Currently Amended) A method for treating a mammal infected with respiratory syncytial virus (RSV), which comprises administering to the mammal a therapeutically effective amount of one or more compounds of formula I:



Formula I

or pharmaceutically acceptable salts or derivatives thereof, wherein

A, together with the atoms to which it is attached, forms an optionally substituted pyridyl ring;

linker ~~–B–C–, together with the atoms to which it is attached, forms~~ is an optionally substituted ~~heterocyclic ring having from 5 to 8 ring atoms~~ linker of the formula –CH<sub>2</sub>(CH<sub>2</sub>)<sub>z</sub>–, where z is 1 or 2;

R<sub>1</sub> is ~~selected from (CH<sub>2</sub>)<sub>n</sub>C<sub>3-7</sub>-cycloalkyl, (CH<sub>2</sub>)<sub>n</sub>C<sub>4-7</sub>-cycloalkenyl, (CH<sub>2</sub>)<sub>n</sub>aryl, (CH<sub>2</sub>)<sub>n</sub>arylC<sub>1-12</sub>-alkyl, (CH<sub>2</sub>)<sub>n</sub>arylC<sub>2-12</sub>-alkenyl, (CH<sub>2</sub>)<sub>n</sub>arylC<sub>2-12</sub>-alkynyl and (CH<sub>2</sub>)<sub>n</sub>heterocyclyl; n is 0-6; and the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups are optionally substituted aryl or heterocyclyl;~~

R<sub>2</sub> is selected from ~~–CH<sub>2</sub>R<sub>3</sub>, –C(Y)R<sub>3</sub>, –C(Y)OR<sub>3</sub>, –C(Y)N(R<sub>4</sub>)R<sub>3</sub>, –C(Y)CH<sub>2</sub>N(R<sub>4</sub>)R<sub>3</sub>, –C(Y)CH<sub>2</sub>SR<sub>3</sub> and –S(O)<sub>w</sub>R<sub>5</sub>; –C(O)R<sub>3</sub> and –C(O)N(R<sub>4</sub>)R<sub>3</sub>, where R<sub>3</sub> is selected from hydrogen, C<sub>1-12</sub>-alkyl, C<sub>2-12</sub>-alkenyl, C<sub>2-12</sub>-alkynyl, (CH<sub>2</sub>)<sub>m</sub>C<sub>3-7</sub>-cycloalkyl, (CH<sub>2</sub>)<sub>m</sub>C<sub>4-7</sub>-cycloalkenyl, (CH<sub>2</sub>)<sub>m</sub>aryl, (CH<sub>2</sub>)<sub>m</sub>arylC<sub>1-12</sub>-alkyl, (CH<sub>2</sub>)<sub>m</sub>arylC<sub>2-12</sub>-alkenyl, (CH<sub>2</sub>)<sub>m</sub>arylC<sub>2-12</sub>-alkynyl and (CH<sub>2</sub>)<sub>m</sub>heterocyclyl; and when R<sub>2</sub> is –CH<sub>2</sub>R<sub>3</sub> or –C(Y)R<sub>3</sub>–C(O)R<sub>3</sub>, R<sub>3</sub> is further selected from –S–R<sub>5</sub> and –O–R<sub>5</sub>; m is 0-3[[6]]; R<sub>4</sub> is hydrogen or C<sub>1-6</sub> alkyl; R<sub>5</sub> is C<sub>1-6</sub>-alkyl, C<sub>2-6</sub>-alkenyl, C<sub>2-6</sub>-alkynyl, C<sub>3-7</sub>-cycloalkyl, C<sub>4-7</sub>-cycloalkenyl, benzyl, aryl or heterocyclyl; w is 0, 1 or 2; and the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups are optionally substituted; and~~

X ~~is and Y are independently selected from O or S.~~


2-8. (Cancelled).

9. (Previously Presented) The method according to claim 1, wherein ring A is optionally substituted with one or more substituents independently selected from halo,  $-\text{NH}_2$ ,  $-\text{NO}_2$ ,  $\text{C}_{1-6}$  alkyl, aryl and heterocyclyl, where the aryl and heterocyclyl groups are optionally substituted with halo,  $\text{C}_{1-6}$  alkyl or halo substituted  $\text{C}_{1-6}$  alkyl, and the optional substituents are further selected from an N-oxide of the pyridyl ring nitrogen and pyridinium salts thereof.

10. (Previously Presented) The method according to claim 9, wherein ring A is optionally substituted with a substituent selected from halo, alkyl,  $\text{C}_6\text{H}_5-$ ,  $\text{CH}_3-\text{C}_6\text{H}_4-$ ,  $\text{CF}_3-\text{C}_6\text{H}_4-$ , pyridyl and  $-\text{NO}_2$ , and the optional substituent is further selected from an N-oxide form of the ring nitrogen, and pyridinium salts thereof.

11. (Previously Presented) The method according to claim 1, wherein ring A is not substituted.

12. (Previously Presented) The method according to claim 1, wherein the compound of formula I is a compound of the formula IV



Formula IV

or an N-oxide or pharmaceutically acceptable salt or derivative thereof.

13. (Currently Amended) The method according to claim 1, wherein  $\text{R}_2$  is selected from  ~~$-\text{CH}_2\text{R}_3$ ,  $-\text{C}(\text{Y})\text{R}_3$ ,  $-\text{C}(\text{Y})\text{OR}_3$ ,  $-\text{C}(\text{Y})\text{N}(\text{R}_4)\text{R}_3$ ,  $-\text{C}(\text{Y})\text{CH}_2\text{N}(\text{R}_4)\text{R}_3$ ,  $-\text{C}(\text{Y})\text{CH}_2\text{SR}_3$  and  $-\text{S}(\text{O})_w\text{R}_5$ ,  $-\text{C}(\text{O})\text{R}_3$  and  $-\text{C}(\text{O})\text{N}(\text{R}_4)\text{R}_3$~~ , where  $\text{R}_3$  is selected from ~~hydrogen,  $\text{C}_{1-12}$  alkyl,  $\text{C}_{2-12}$  alkenyl,  $\text{C}_{2-12}$  alkynyl,  $(\text{CH}_2)_m\text{C}_{3-7}$  cycloalkyl,  $(\text{CH}_2)_m\text{C}_{4-7}$  cycloalkenyl,  $(\text{CH}_2)_m$  aryl[[,]]  $-(\text{CH}_2)_m$  aryl $\text{C}_{1-12}$  alkyl,  $(\text{CH}_2)_m$  aryl $\text{C}_{2-12}$  alkenyl,  $(\text{CH}_2)_m$  aryl $\text{C}_{2-12}$  alkynyl and  $(\text{CH}_2)_m$  heterocyclyl~~, and when  $\text{R}_2$  is  ~~$-\text{CH}_2\text{R}_3$  or  $-\text{C}(\text{Y})\text{R}_3$~~   $-\text{C}(\text{O})\text{R}_3$ ,  $\text{R}_3$  is further selected from  $-\text{S}-\text{R}_5$  and  $-\text{O}-\text{R}_5$ ;  $m$  is 0-3[[6]];  $\text{R}_4$  is hydrogen or is  $\text{C}_{1-6}$  alkyl;  ~~$\text{R}_5$  is selected from  $\text{C}_{1-6}$  alkyl,  $\text{C}_{2-6}$  alkenyl,  $\text{C}_{2-6}$  alkynyl,  $\text{C}_{3-7}$  cycloalkyl,  $\text{C}_{4-7}$  cycloalkenyl, benzyl, aryl and heterocyclyl~~;  $w$  is 0, 1

~~or 2;~~ and the alkyl, ~~alkenyl, alkynyl, cycloalkyl, cycloalkenyl,~~ aryl and heterocyclyl groups are optionally substituted with one or more substituents selected from C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, halo, halo-C<sub>1-6</sub> alkyl, CF<sub>3</sub>, hydroxy, mercapto, nitro, cyano, NH<sub>2</sub>, mono and di(C<sub>1-6</sub> alkyl)amino, phenyl, benzyl and heterocyclyl.

14-15. (Cancelled).

16. (Currently Amended) The method according to claim 1 ~~14 or 15~~, wherein R<sub>3</sub> is optionally substituted and is selected from phenyl, naphthyl, furyl, thienyl, pyrrolyl, *H*-pyrrolyl, pyrrolinyl, pyrrolidinyl, oxazolyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, thiazolyl, isoxazolyl, furazanyl, isothiazolyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, triazolyl, 1,2,3-triazolyl, 1,3,4-triazolyl, tetrazolyl, thiadiazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyranyl, pyrazinyl, piperidinyl, 1,4-dioxanyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, piperazinyl, 1,3,5-trithianyl, triazinyl, 1*H*-thieno[2,3-*c*]pyrazolyl, thieno[2,3-*b*]furyl, indolyl, isoindolyl, benzofuranyl, benzothienyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, indazolyl, isoquinolinyl, quinolinyl, quinoxalinyl, uridiny, purinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, benzotriazinyl, naphthyridinyl and pteridinyl.

17. (Previously Presented) The method according to claim 16, wherein R<sub>3</sub> is optionally substituted with one or more substituents selected from C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, halo, halo-C<sub>1-6</sub> alkyl, CF<sub>3</sub>, hydroxy, mercapto, nitro, cyano, NH<sub>2</sub>, mono and di(C<sub>1-6</sub> alkyl) amino, phenyl, benzyl and heterocyclyl.

18-20. (Cancelled).

21. (Previously Presented) The method according to claim 1, wherein -B-C- is a linker of the formula -CH<sub>2</sub>CH<sub>2</sub>-.

22. (Previously Presented) The method according to claim 1, wherein linker -B-C- is optionally substituted with no more than three optional substituents, the substituents selected from halo, lower alkyl, hydroxy, lower alkoxy, phenyl and benzyl.

23. (Previously Presented) The method according to claim 1, wherein linker -B-C- is not substituted.

24-25. (Cancelled).

26. (Currently Amended) The method according to claim 1, wherein  $R_1$  represents phenyl, thienyl, pyrrolyl, pyridyl, or pyridyl ~~or  $C_{1-6}$  alkylphenyl~~, each optionally substituted with halo, hydroxy, nitro,  $-NR'R''$ ,  $C_{1-12}$  alkyl, phenyl or  $-OR_a$ , where  $R'$  and  $R''$  are independently selected from hydrogen, lower alkyl and  $-C(O)R$ , where  $R$  is  $C_{1-6}$  alkyl, phenyl or heterocyclyl;  $R_a$  is  $-C_{1-12}$  alkyl,  $-C_{3-7}$  cycloalkyl,  $-C_{1-12}$  alkyl $C_{3-7}$  cycloalkyl, phenyl or  $-C_{1-12}$  alkylphenyl; and the  $C_{1-12}$  alkyl, phenyl or  $R_a$  group is optionally substituted with halo,  $-CN$ ,  $-NR^{10}R^{11}$ ,  $-CO_2R^{12}$  or  $-CONR^{10}R^{11}$ , where  $R^{10}$ ,  $R^{11}$  and  $R^{12}$  are independently selected from hydrogen and lower alkyl.

27. (Previously Presented) The method according to claim 1, wherein  $R_1$  is phenyl optionally substituted with a substituent selected from halo,  $-C_{1-6}$  alkyl,  $-C_{1-6}$  alkylhalo,  $-C_{1-6}$  alkylCN,  $-OC_{1-6}$  alkyl,  $-OC_{1-6}$  alkylhalo,  $-OC_{1-6}$  alkylCO<sub>2</sub>NH<sub>2</sub>,  $-OC_{1-6}$  alkylCN,  $-OC_{1-6}$  alkyl $C_{3-7}$  cycloalkyl,  $-OC_{1-6}$  alkylC<sub>6</sub>H<sub>5</sub>,  $-OC_{1-6}$  alkylOCH<sub>3</sub>,  $-OC_6H_5$ ,  $-OC_6H_4$ halo,  $-CF_3$ ,  $-OCF_3$ ,  $-NR'R''$ ,  $-CO_2H$ ,  $-CO_2C_{1-6}$  alkyl,  $-NO_2$ ,  $-OH$ ,  $-C_6H_5$ ,  $-C_6H_4C_{1-6}$  alkyl,  $-C_6H_4$ halo and  $-OC(O)C_{1-6}$  alkyl; where  $R'$  and  $R''$  are independently selected from hydrogen,  $-C(O)C_{1-6}$  alkyl,  $-C(O)C_6H_5$ ,  $-C(O)CH=CHCO_2H$ ,  $-C(O)C_{1-6}$  alkylCO<sub>2</sub>H,  $-C(O)C_{1-6}$  alkylCO<sub>2</sub>CH<sub>3</sub>,  $-C(O)C_{1-6}$  alkylC<sub>6</sub>H<sub>5</sub>,  $-C(O)C_{1-6}$  alkylC<sub>6</sub>H<sub>4</sub>CH<sub>3</sub>,  $-C(O)C_{1-6}$  alkylC<sub>6</sub>H<sub>4</sub>OCH<sub>3</sub> and  $-C(O)C_{1-6}$  alkylC<sub>6</sub>H<sub>4</sub>halo.

28. (Previously Presented) The method according to claim 1, wherein  $R_1$  is phenyl substituted with halo,  $-OC_{1-6}$  alkyl,  $-OC_{1-6}$  alkylhalo,  $-OC_{1-6}$  alkylCO<sub>2</sub>NH<sub>2</sub>,  $-OC_{1-6}$  alkylCN,  $-OC_{1-6}$  alkyl $C_{3-7}$  cycloalkyl,  $-OC_{1-6}$  alkylC<sub>6</sub>H<sub>5</sub> or  $-OC_{1-6}$  alkylOCH<sub>3</sub>.

29. (Previously Presented) The method according to claim 1, wherein  $R_1$  is 4-chlorophenyl.


30. (Previously Presented) A method for the treatment of infections involving RSV by the inhibition of virus fusion processes, comprising administering a therapeutically effective amount of a compound of formula I as defined in claim 1, or a pharmaceutically acceptable salt or derivative thereof, to a patient in need of treatment.

31. (Previously Presented) A pharmaceutical formulation, comprising a compound of formula I as defined in claim 1, or a pharmaceutically acceptable salt or derivative thereof, and a pharmaceutically acceptable carrier or excipient.

32-36. (Cancelled).

37. (Previously Presented) The method of claim 1 for the treatment of human RSV.

38. (Currently Amended) A compound of formula I



Formula I

or a salt or pharmaceutically acceptable derivative thereof, wherein:

A, together with the atoms to which it is attached, represents an optionally substituted pyridyl, ~~optionally substituted pyridazinyl, optionally substituted pyrimidinyl or optionally substituted pyrazinyl ring;~~

–B–C– is an optionally substituted linker of the formula  $-\text{CH}_2-(\text{CH}_2)_z-$ , where z is 1-4;

R<sub>1</sub> is selected from C<sub>1-12</sub> alkyl, C<sub>2-12</sub> alkenyl, C<sub>2-12</sub> alkynyl,  $-(\text{CH}_2)_n\text{C}_{3-7}$  cycloalkyl,  $-(\text{CH}_2)_n\text{C}_{4-7}$  cycloalkenyl,  $-(\text{CH}_2)_n$  aryl,  $-(\text{CH}_2)_n$  arylC<sub>1-12</sub> alkyl,  $-(\text{CH}_2)_n$  arylC<sub>2-12</sub> alkenyl,  $-(\text{CH}_2)_n$  arylC<sub>2-12</sub> alkynyl and  $-(\text{CH}_2)_n$  heterocyclyl; n is 0-6; and the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups are optionally substituted;

R<sub>2</sub> is selected from  $-\text{CH}_2\text{R}_3$ ,  $-\text{C}(\text{Y})\text{R}_3$ ,  $-\text{C}(\text{Y})\text{OR}_3$ ,  $-\text{C}(\text{Y})\text{N}(\text{R}_4)\text{R}_3$  and  $-\text{S}(\text{O})_w\text{R}_5$ , where R<sub>3</sub> is selected from ~~hydrogen, C<sub>1-12</sub> alkyl, C<sub>2-12</sub> alkenyl, C<sub>2-12</sub> alkynyl,~~  $-(\text{CH}_2)_m\text{C}_{3-7}$  cycloalkyl,  $-(\text{CH}_2)_m\text{C}_{4-7}$  cycloalkenyl,  $-(\text{CH}_2)_m$  aryl,  $-(\text{CH}_2)_m$  arylC<sub>1-12</sub> alkyl,  $-(\text{CH}_2)_m$  arylC<sub>2-12</sub> alkenyl,  $-(\text{CH}_2)_m$  arylC<sub>2-12</sub> alkynyl and  $-(\text{CH}_2)_m$  heterocyclyl; and when R<sub>2</sub> is  $-\text{CH}_2\text{R}_3$  or  $-\text{C}(\text{Y})\text{R}_3$ , R<sub>3</sub> is further selected from  $-\text{S}-\text{R}_5$  and  $-\text{O}-\text{R}_5$ ; m is 0-6; R<sub>4</sub> is hydrogen or C<sub>1-6</sub> alkyl; R<sub>5</sub> is C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>3-7</sub> cycloalkyl, C<sub>4-7</sub> cycloalkenyl, benzyl, aryl or heterocyclyl; w is 0, 1 or 2; and the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups are optionally substituted; ~~with the proviso that R<sub>2</sub> is not unsubstituted C<sub>1-6</sub> alkyl;~~ and

X and Y are independently selected from O, S and NR<sub>6</sub>, where R<sub>6</sub> is independently selected from hydrogen, lower alkyl, hydroxy and lower alkoxy;

~~with the provisos that when A is pyridyl and R<sub>1</sub> is 3-CH<sub>3</sub>-4-CH<sub>3</sub>CH<sub>2</sub>CH<sub>2</sub>NHC(O)CH<sub>2</sub>O-phenyl, R<sub>2</sub> is not CH<sub>3</sub>; and when A is pyridyl, X is O, R<sub>1</sub> is  $-(\text{CH}_2)_n$  aryl, n is 0, and R<sub>2</sub> is  $-\text{CH}_2\text{R}_3$ , then (i) R<sub>3</sub> is not methyl when R<sub>4</sub> is 4-chlorophenyl and z is 1, and (ii) R<sub>3</sub> is not ethyl when R<sub>4</sub> is phenyl and z is 2.~~

39-40. (Cancelled).

41. (Currently Amended) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein ring A is optionally substituted with one or more substituents independently selected from halo,  $-NH_2$ ,  $-NO_2$ ,  $C_{1-6}$  alkyl, aryl and heterocyclyl, where the aryl and heterocyclyl groups are optionally substituted with halo,  $C_{1-6}$  alkyl or halo substituted  $C_{1-6}$  alkyl, and, ~~when ring A contains one or more ring nitrogens, the optional substituents are also selected from an N-oxide[[s]] of one or more of the pyridyl ring nitrogen[[s]].~~

42. (Currently Amended) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein ring A is optionally substituted with a substituent selected from halo, alkyl,  $C_6H_5-$ ,  $CH_3-C_6H_4-$ ,  $CF_3-C_6H_4-$ , pyridyl and  $-NO_2$ , and ~~when ring A contains one or more ring nitrogens, the optional substituent is also selected from an N-oxide form[[s]] of the pyridyl ring nitrogen[[s]].~~

43. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein ring A is not substituted.

44. (Currently Amended) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein  $R_2$  is selected from  $-CH_2R_3$ ,  $-C(Y)R_3$ ,  $-C(Y)OR_3$ ,  $-C(Y)N(R_4)R_3$ ,  $-C(Y)CH_2N(R_4)R_3$ ,  $-C(Y)CH_2SR_3$  and  $-S(O)_wR_5$ , where  $R_3$  is selected from ~~hydrogen,  $C_{1-12}$  alkyl,  $C_{2-12}$  alkenyl,  $C_{2-12}$  alkynyl,~~  $-(CH_2)_mC_{3-7}$  cycloalkyl,  $-(CH_2)_mC_{4-7}$  cycloalkenyl,  $-(CH_2)_m$  aryl,  $-(CH_2)_m$  aryl $C_{1-12}$  alkyl,  $-(CH_2)_m$  aryl $C_{2-12}$  alkenyl,  $-(CH_2)_m$  aryl $C_{2-12}$  alkynyl and  $-(CH_2)_m$  heterocyclyl, and when  $R_2$  is  $-CH_2R_3$  or  $-C(Y)R_3$ ,  $R_3$  is further selected from  $-S-R_5$  and  $-O-R_5$ ; m is 0-6,  $R_4$  is hydrogen or  $C_{1-6}$  alkyl,  $R_5$  is selected from  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{3-7}$  cycloalkyl,  $C_{4-7}$  cycloalkenyl, benzyl, aryl and heterocyclyl; w is 0, 1 or 2, and the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups are optionally substituted with one or more substituents selected from  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl, halo, halo- $C_{1-6}$  alkyl,  $CF_3$ , hydroxy, mercapto, nitro, cyano,  $NH_2$ , mono and di( $C_{1-6}$  alkyl) amino, phenyl, benzyl and heterocyclyl, the substituents being optionally substituted.

45. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein  $R_2$  is  $-\text{CH}_2-\text{R}_3$ ; and  $R_3$  is  $-(\text{CH}_2)_m$  aryl or  $-(\text{CH}_2)_m$  heterocyclyl;  $m$  is 0 to 3; and the aryl or heterocyclyl ring is optionally substituted.

46. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein  $R_2$  is  $-\text{COR}_3$ , and  $R_3$  is optionally substituted aryl or optionally substituted heterocyclyl.

47. (Previously Presented) The compound according to claim 46, or a salt or pharmaceutically acceptable derivative thereof, wherein  $R_3$  is optionally substituted and is selected from phenyl, naphthyl, furyl, thienyl, pyrrolyl, *H*-pyrrolyl, pyrrolinyl, pyrrolidinyl, oxazolyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, thiazolyl, isoxazolyl, furazanyl, isothiazolyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, imidazolyl, imidazolinyl, triazolyl, 1,2,3-triazolyl, 1,3,4-triazolyl, tetrazolyl, thiadiazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyranyl, pyrazinyl, piperidinyl, 1,4-dioxanyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, piperazinyl, 1,3,5-trithianyl, triazinyl, 1*H*-thieno[2,3-*c*]pyrazolyl, thieno[2,3-*b*]furyl, indolyl, isoindolyl, benzofuranyl, benzothienyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, indazolyl, isoquinolinyl, quinolinyl, quinoxalinyl, uridiny, purinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, benzotriazinyl, naphthyridinyl and pteridinyl.

48. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein  $R_3$  is optionally substituted with one or more substituents selected from  $\text{C}_{1-6}$  alkyl,  $\text{C}_{1-6}$  alkoxy,  $\text{C}_{2-6}$  alkenyl,  $\text{C}_{2-6}$  alkynyl, halo, halo- $\text{C}_{1-6}$  alkyl,  $\text{CF}_3$ , hydroxy, mercapto, nitro, cyano,  $\text{NH}_2$ , mono and di( $\text{C}_{1-6}$  alkyl) amino, phenyl, benzyl and heterocyclyl, where the phenyl, benzyl and heterocyclyl groups are optionally substituted.

49. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein  $R_2$  is  $-\text{CON}(\text{H})\text{R}_3$ ;  $R_3$  is  $-(\text{CH}_2)_m$  aryl or  $-(\text{CH}_2)_m$  heteroaryl;  $m$  is 0 to 2; and the aryl or heteroaryl ring is optionally substituted with one or more substituents independently selected from halo, lower alkyl, hydroxy, lower alkoxy and phenyl.

50. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein  $z$  is 1 or 2.

51. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein  $-B-C-$  is a linker of the formula  $-CH_2CH_2-$ .

52. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein the linker  $-B-C-$  is optionally substituted no more than three optional substituents, the substituents selected from halo, lower alkyl, hydroxy, lower alkoxy, phenyl and benzyl.

53. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein the linker  $-B-C-$  is not substituted.

54. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein X is oxygen or sulphur.

55. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein X is oxygen.

56. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein  $R_1$  is an optionally substituted aryl or heterocyclyl group.

57. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein  $R_1$  represents phenyl, thienyl, pyrrolyl, pyridyl or  $-C_{1-6}$  alkylphenyl, each optionally substituted with halo, hydroxy, nitro,  $-NR'R''$ ,  $C_{1-12}$  alkyl, phenyl or  $-O-R_a$ , where  $R'$  and  $R''$  are independently selected from hydrogen, lower alkyl and  $-C(O)R$ , where  $R$  is  $C_{1-6}$  alkyl, phenyl or heterocyclyl;  $R_a$  is  $-C_{1-12}$  alkyl,  $-C_{3-7}$  cycloalkyl,  $-C_{1-12}$  alkyl $C_{3-7}$  cycloalkyl, phenyl or  $-C_{1-12}$  alkylphenyl; and the  $C_{1-12}$  alkyl, phenyl or  $R_a$  group is optionally substituted with halo,  $-CN$ ,  $-NR^{10}R^{11}$ ,  $-CO_2R^{12}$  or  $-CONR^{10}R^{11}$ , where  $R^{10}$ ,  $R^{11}$  and  $R^{12}$  are independently selected from hydrogen and lower alkyl.

58. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein  $R_1$  is phenyl optionally substituted with a substituent selected from halo,  $-C_{1-6}$  alkyl,  $-C_{1-6}$  alkylhalo,  $-C_{1-6}$  alkylCN,  $-OC_{1-6}$  alkyl,  $-OC_{1-6}$  alkylhalo,  $-OC_{1-6}$  alkyl $CO_2NH_2$ ,  $-OC_{1-6}$  alkylCN,  $-OC_{1-6}$  alkyl $C_{3-7}$  cycloalkyl,  $-OC_{1-6}$  alkyl $C_6H_5$ ,  $-OC_{1-6}$  alkyl $OCH_3$ ,  $-OC_6H_5$ ,  $-OC_6H_4$ halo,  $-CF_3$ ,  $-OCF_3$ ,  $-NR'R''$ ,  $-CO_2H$ ,  $-CO_2C_{1-6}$  alkyl,

$-\text{NO}_2$ ,  $-\text{OH}$ ,  $-\text{C}_6\text{H}_5$ ,  $-\text{C}_6\text{H}_4\text{C}_{1-6}$  alkyl,  $-\text{C}_6\text{H}_4\text{halo}$  and  $-\text{OC}(\text{O})\text{C}_{1-6}$  alkyl; where  $\text{R}'$  and  $\text{R}''$  are independently selected from hydrogen,  $-\text{C}(\text{O})\text{C}_{1-6}$  alkyl,  $-\text{C}(\text{O})\text{C}_6\text{H}_5$ ,  $-\text{C}(\text{O})\text{CH}=\text{CHCO}_2\text{H}$ ,  $-\text{C}(\text{O})\text{C}_{1-6}$  alkyl $\text{CO}_2\text{H}$ ,  $-\text{C}(\text{O})\text{C}_{1-6}$  alkyl $\text{CO}_2\text{CH}_3$ ,  $-\text{C}(\text{O})\text{C}_{1-6}$  alkyl $\text{C}_6\text{H}_5$ ,  $-\text{C}(\text{O})\text{C}_{1-6}$  alkyl $\text{C}_6\text{H}_4\text{CH}_3$ ,  $-\text{C}(\text{O})\text{C}_{1-6}$  alkyl $\text{C}_6\text{H}_4\text{OCH}_3$  and  $-\text{C}(\text{O})\text{C}_{1-6}$  alkyl $\text{C}_6\text{H}_4\text{halo}$ .


59. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein  $\text{R}_1$  is halo-phenyl.

60. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein  $\text{R}_1$  is 4-chlorophenyl.

61. (Cancelled).

62. (Previously Presented) The compound according to claim 38, or a salt or pharmaceutically acceptable derivative thereof, wherein  $\text{R}_2$  is  $-\text{C}(\text{O})-\text{R}_3$  and  $\text{R}_3$  is  $-(\text{CH}_2)_m\text{-aryl}$  or  $-(\text{CH}_2)_m\text{-heteroaryl}$ , where  $m$  is 0 to 6, and the aryl or heteroaryl group is optionally substituted.

63. (Previously Presented) The compound according to claim 38 of the formula IV



Formula IV

or an N-oxide form or pyridinium salt thereof.

64. (Previously Presented) The compound according to claim 63, or an N-oxide form or pyridinium salt thereof, wherein  $\text{R}_2$  is  $-\text{C}(\text{O})\text{R}_3$  and  $\text{R}_3$  is  $-(\text{CH}_2)_m\text{-aryl}$  or  $-(\text{CH}_2)_m\text{-heteroaryl}$ , where  $m$  is 0 to 6, and the aryl or heteroaryl group is optionally substituted.

65. (Currently Amended) A compound selected from the group consisting of:~~disclosed in table 2 or 3~~

9*b*-(4-chloro-phenyl)-1-(4-fluoro-benzoyl)-1,2,3,9*b*-tetrahydroimidazo[1',2':1,5]-pyrrolo[3,4-*b*]pyridin-5-one;

3a-(4-chloro-phenyl)-3-(4-fluoro-benzoyl)-1,2,3,3a-tetrahydro-3,6,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(4-fluoro-benzoyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3-(4-fluoro-benzoyl)-3a-p-tolyl-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3-[2-(4-methoxy-phenyl)-acetyl]-3a-p-tolyl-1,2,3,3a-tetrahydro-3,6,8a-triaza-cyclopenta[a]inden-8-one;

3a-(2-chloro-phenyl)-3-(4-fluoro-benzoyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-[2-(4-methoxy-phenyl)-acetyl]-1,2,3,3a-tetrahydro-3,6,8a-triaza-cyclopenta[a]inden-8-one;

3-(4-fluoro-benzoyl)-3a-(4-trifluoromethyl-phenyl)-1,2,3,3a-tetrahydro-3,6,8a-triaza-cyclopenta[a]inden-8-one;

3-[2-(4-methoxy-phenyl)-acetyl]-3a-(4-trifluoromethyl-phenyl)-1,2,3,3a-tetrahydro-3,6,8a-triaza-cyclopenta[a]inden-8-one;

3-[2-(4-methoxy-phenyl)-acetyl]-3a-(4-trifluoromethyl-phenyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-[2-(4-methoxy-phenyl)-acetyl]-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(4-fluoro-benzoyl)-5-oxy-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3-(4-fluoro-benzoyl)-3a-(4-methoxy-phenyl)-1,2,3,3a-tetrahydro-3,6,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-bromo-phenyl)-3-(4-fluoro-benzoyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-bromo-phenyl)-3-(4-fluoro-benzoyl)-1,2,3,3a-tetrahydro-3,6,8a-triaza-cyclopenta[a]inden-8-one;

9b-(4-chloro-phenyl)-1-(4-fluoro-benzoyl)-1,2,3,9b-tetrahydroimidazo[1',2':1,2]-pyrrolo[3,4-b]pyridin-5-one;

3a-(4-ethyl-phenyl)-3-(4-fluoro-benzoyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(pyridine-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(6-chloro-pyridine-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(6-chloro-pyridazine-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-bromo-phenyl)-3-(6-fluoro-pyridine-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-bromo-phenyl)-3-(6-fluoro-pyridine-3-carbonyl)-1,2,3,3a-tetrahydro-3,6,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(6-fluoro-pyridine-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

9b-(4-chloro-phenyl)-1-(6-fluoro-pyridine-3-carbonyl)-1,2,3,9b-tetrahydroimidazo[1',2':1,2]pyrrolo[3,4-b]pyridin-5-one;

9b-(4-chloro-phenyl)-1-(6-fluoro-pyridine-3-carbonyl)-1,2,3,9b-tetrahydroimidazo[1',2':1,5]pyrrolo[3,4-b]pyridin-5-one;

3a-(4-ethyl-phenyl)-3-[2-(4-methoxy-phenyl)-acetyl]-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-ethyl-phenyl)-3-(4-fluoro-benzoyl)-5-oxy-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-ethyl-phenyl)-3-[2-(4-methoxy-phenyl)-acetyl]-5-oxy-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-ethyl-phenyl)-3-(6-fluoro-pyridine-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(6-phenoxy-pyridine-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(2-thiophen-2-yl-thiazole-4-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(4,5,6,7-tetrahydro-benzo[c]thiophene-1-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3-(benzo[b]thiophene-3-carbonyl)-3a-(4-chloro-phenyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(quinoline-2-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(2-pyridin-3-yl-thiazole-4-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(5-methyl-isoxazole-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(6-morpholin-4-yl-pyridine-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(1,3-dimethyl-1H-thieno[2,3-c]pyrazole-5-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(5-methyl-2-trifluoromethyl-furan-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(4-methyl-[1,2,3]thiadiazole-5-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(5-methyl-2-phenyl-2H-[1,2,3]triazole-4-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(5-phenyl-thiophene-2-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(4-phenyl-[1,2,3]thiadiazole-5-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-[1-(4-fluoro-phenyl)-5-methyl-1H-pyrazole-4-carbonyl]-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(2-phenyl-thiazole-4-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(3,5-dimethyl-isoxazole-4-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(1,3,5-trimethyl-1H-pyrazole-4-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(2-methyl-5-phenyl-furan-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3-[2-(4-chloro-phenoxy)-pyridine-3-carbonyl]-3a-(4-chloro-phenyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-[2-(4-fluoro-phenoxy)-pyridine-3-carbonyl]-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(2-ethylsulfanyl-pyridine-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(2-methylsulfanyl-pyridine-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(2-pentylsulfanyl-pyridine-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(2-phenylsulfanyl-pyridine-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(2-propylsulfanyl-pyridine-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(2-p-tolylsulfanyl-pyridine-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(2-chloro-pyridine-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(2-phenoxy-pyridine-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3-(5-bromo-pyridine-3-carbonyl)-3a-(4-chloro-phenyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(5-phenylethynyl-pyridine-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3-[3a-(4-chloro-phenyl)-8-oxo-1,2,3a,8-tetrahydro-3,5,8a-triaza-cyclopenta[a]indene-3-carbonyl]-isonicotinic acid methyl ester;

3a-(4-chloro-phenyl)-3-(5-hex-1-ynyl-pyridine-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(5-thiophen-2-yl-pyridine-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-[6-(2,2,2-trifluoro-ethoxy)-pyridine-3-carbonyl]-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-[3-methyl-5-(4-methyl-[1,2,3]thiadiazol-5-yl)-isoxazole-4-carbonyl]-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(2,5-dimethyl-furan-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(furan-2-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(furan-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(4,5-dimethyl-furan-2-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(5-phenylethynyl-furan-2-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

4-[3a-(4-chloro-phenyl)-8-oxo-1,2,3a,8-tetrahydro-3,5,8a-triaza-cyclopenta[a]indene-3-carbonyl]-5-methyl-furan-2-sulfonic acid dimethylamide;

3a-(4-chloro-phenyl)-3-[1-(4-chloro-phenyl)-5-methyl-1H-pyrazole-4-carbonyl]-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-[1-(4-methoxy-phenyl)-5-methyl-1H-pyrazole-4-carbonyl]-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(2,5-dimethyl-2H-pyrazole-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(1,5-dimethyl-1H-pyrazole-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(2-ethyl-5-methyl-2H-pyrazole-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(2-phenyl-2H-pyrazole-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(1-phenyl-5-propyl-1H-pyrazole-4-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3-(5-tert-butyl-2-methyl-2H-pyrazole-3-carbonyl)-3a-(4-chloro-phenyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3-(4-bromo-2,5-dimethyl-2H-pyrazole-3-carbonyl)-3a-(4-chloro-phenyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3-(4-bromo-2-ethyl-5-methyl-2H-pyrazole-3-carbonyl)-3a-(4-chloro-phenyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(5-methyl-1-*o*-tolyl-1*H*-pyrazole-4-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[*a*]inden-8-one;

3a-(4-chloro-phenyl)-3-(5-methyl-1-phenyl-1*H*-pyrazole-4-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[*a*]inden-8-one;

3a-(4-chloro-phenyl)-3-(thiophene-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[*a*]inden-8-one;

3a-(4-chloro-phenyl)-3-(thiophene-2-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[*a*]inden-8-one;

3a-(4-chloro-phenyl)-3-(thienof[3,2-*b*]thiophene-2-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[*a*]inden-8-one;

3a-(4-chloro-phenyl)-3-(5-pyridin-2-yl-thiophene-2-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[*a*]inden-8-one;

3a-(4-chloro-phenyl)-3-(5-nitro-thiophene-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[*a*]inden-8-one;

3a-(4-chloro-phenyl)-3-(5-nitro-benzo[*b*]thiophene-2-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[*a*]inden-8-one;

3-(5-chloro-4-methoxy-thiophene-3-carbonyl)-3a-(4-chloro-phenyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[*a*]inden-8-one;

3-(5-bromo-thiophene-2-carbonyl)-3a-(4-chloro-phenyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[*a*]inden-8-one;

3-(5-bromo-4-methoxy-thiophene-3-carbonyl)-3a-(4-chloro-phenyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[*a*]inden-8-one;

3a-(4-chloro-phenyl)-3-(5-methanesulfonyl-thiophene-2-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[*a*]inden-8-one;

3a-(4-chloro-phenyl)-3-[5-(2-methyl-thiazol-4-yl)-thiophene-2-carbonyl]-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[*a*]inden-8-one;

3a-(4-chloro-phenyl)-3-(4-methoxy-thiophene-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[*a*]inden-8-one;

3a-(4-chloro-phenyl)-3-(3-chloro-thiophene-2-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[*a*]inden-8-one;

3-(3-chloro-4-methanesulfonyl-thiophene-2-carbonyl)-3a-(4-chloro-phenyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[*a*]inden-8-one;

3a-(4-chloro-phenyl)-3-(2-methyl-thiazole-4-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3-(3-bromo-thiophene-2-carbonyl)-3a-(4-chloro-phenyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3-([2,2']bithiophenyl-5-carbonyl)-3a-(4-chloro-phenyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3-(benzo[b]thiophene-2-carbonyl)-3a-(4-chloro-phenyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(isoxazole-5-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(3-ethoxy-thiophene-2-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3-(3-chloro-4-methyl-thiophene-2-carbonyl)-3a-(4-chloro-phenyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(3-methyl-5-phenyl-isoxazole-4-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

6-[3a-(4-chloro-phenyl)-8-oxo-1,2,3a,8-tetrahydro-3,5,8a-triaza-cyclopenta[a]indene-3-carbonyl]-nicotinic acid methyl ester;

3a-(4-chloro-phenyl)-3-(6-chloro-pyridine-2-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3-(5-chloro-2-methylsulfanyl-pyrimidine-4-carbonyl)-3a-(4-chloro-phenyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(pyridine-2-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-([1,2,3]thiadiazole-4-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(2-pyridin-4-yl-thiazole-4-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(4-methyl-2-pyrazin-2-yl-thiazole-5-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3-(benzofuran-2-carbonyl)-3a-(4-chloro-phenyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3-(benzo[c]isoxazole-3-carbonyl)-3a-(4-chloro-phenyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(4,5-dichloro-isothiazole-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-[5-(4-methoxy-phenyl)-oxazole-4-carbonyl]-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(5-phenyl-oxazole-4-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(4-isopropyl-[1,2,3]thiadiazole-5-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-[3-(4-methoxy-phenyl)-isoxazole-5-carbonyl]-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-[3-(4-chloro-phenyl)-isoxazole-5-carbonyl]-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(1-methyl-3-trifluoromethyl-1H-pyrazole-4-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(4-methyl-2-pyridin-2-yl-thiazole-5-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(2-p-tolyl-thiazole-4-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(4-methyl-2-thiophen-2-yl-thiazole-5-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-[2-(4-chloro-phenyl)-thiazole-4-carbonyl]-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(3-phenyl-isoxazole-5-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(4-methyl-2-pyridin-3-yl-thiazole-5-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3-(2-chloro-5-isopropyl-thiazole-4-carbonyl)-3a-(4-chloro-phenyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-[5-methyl-1-(4-nitro-phenyl)-1H-[1,2,4]triazole-3-carbonyl]-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-[2-(4-methoxy-phenyl)-thiazole-4-carbonyl]-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(4-methyl-2-phenyl-thiazole-5-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(5-methyl-1H-pyrazole-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-[3-(2-chloro-phenyl)-isoxazole-5-carbonyl]-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(6-fluoro-pyridine-3-carbonyl)-5-oxy-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(pyrimidine-5-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-5-oxy-3-[2-(1-oxy-pyridin-3-yl)-thiazole-4-carbonyl]-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(thiazole-4-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(4-methyl-furazan-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(5-isobutyl-isoxazole-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(5-isopropyl-2-phenyl-2H-pyrazole-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(5-furan-2-yl-isoxazole-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(4,5,6,7-tetrahydro-benzo[a]isoxazole-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(5-pyrazol-1-ylmethyl-furan-2-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-[5-(4-chloro-phenyl)-isoxazole-3-carbonyl]-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3a-(4-chloro-phenyl)-3-(5-phenyl-isoxazole-3-carbonyl)-1,2,3,3a-tetrahydro-3,5,8a-triaza-cyclopenta[a]inden-8-one;

3-(5-*tert*-butyl-2-phenyl-2*H*-pyrazole-3-carbonyl)-3*a*-(4-chloro-phenyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triazacyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-(4-fluoro-benzyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triazacyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-furan-2-ylmethyl-1,2,3,3*a*-tetrahydro-3,5,8*a*-triazacyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-3-pyridin-3-ylmethyl-1,2,3,3*a*-tetrahydro-3,5,8*a*-triazacyclopenta[*a*]inden-8-one;

3*a*-(4-chloro-phenyl)-8-oxo-1,2,3*a*,8-tetrahydro-3,5,8*a*-triazacyclopenta[*a*]indene-3-carboxylic acid benzylamide;

3*a*-(4-chloro-phenyl)-8-oxo-1,2,3*a*,8-tetrahydro-3,5,8*a*-triazacyclopenta[*a*]indene-3-carboxylic acid phenylamide;


3*a*-(4-chloro-phenyl)-8-oxo-1,2,3*a*,8-tetrahydro-3,5,8*a*-triazacyclopenta[*a*]indene-3-carbothioic acid benzylamide;

3*a*-(4-chloro-phenyl)-8-oxo-1,2,3*a*,8-tetrahydro-3,5,8*a*-triazacyclopenta[*a*]indene-3-carbothioic acid phenylamide; and

3*a*-(4-chloro-phenyl)-3-(toluene-4-sulfonyl)-1,2,3,3*a*-tetrahydro-3,5,8*a*-triazacyclopenta[*a*]inden-8-one.

66. (Previously Presented) A pharmaceutical formulation comprising a compound of formula I according to claim 38, or a pharmaceutically acceptable salt or derivative thereof, and a pharmaceutically acceptable carrier or excipient.

67. (Withdrawn) A compound of formula



or a salt thereof, wherein:

the pyridyl ring is optionally substituted;

–B–C– is an optionally substituted linker of the formula –CH<sub>2</sub>–(CH<sub>2</sub>)<sub>z</sub>–, where z is 1-4;

R<sub>1</sub> is selected from C<sub>1-12</sub> alkyl, C<sub>2-12</sub> alkenyl, C<sub>2-12</sub> alkynyl, –(CH<sub>2</sub>)<sub>n</sub>C<sub>3-7</sub> cycloalkyl, –(CH<sub>2</sub>)<sub>n</sub>C<sub>4-7</sub> cycloalkenyl, –(CH<sub>2</sub>)<sub>n</sub> aryl, –(CH<sub>2</sub>)<sub>n</sub> arylC<sub>1-12</sub> alkyl, –(CH<sub>2</sub>)<sub>n</sub> arylC<sub>2-12</sub> alkenyl, –(CH<sub>2</sub>)<sub>n</sub> arylC<sub>2-12</sub> alkynyl and –(CH<sub>2</sub>)<sub>n</sub> heterocyclyl; where n is 0-6, and the alkyl, alkenyl,

alkynyl, cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups are optionally substituted; and

X is selected from O, S and  $\text{NR}_6$ , where  $\text{R}_6$  is independently selected from hydrogen, lower alkyl, hydroxy and lower alkoxy;

with the proviso that when  $-\text{B}-\text{C}-$  is  $-\text{CH}_2\text{CH}(\text{CH}(\text{CH}_3)_2)-$ ,  $\text{R}_1$  is not 3- $\text{CH}_3$ -4- $\text{CH}_3\text{CH}_2\text{CH}_2\text{NHC}(\text{O})\text{CH}_2\text{O}$ -phenyl-.

68. (Withdrawn) The compound according to claim 67 or a salt thereof, wherein the pyridyl ring is optionally substituted with one or more substituents independently selected from halo,  $-\text{NH}_2$ ,  $-\text{NO}_2$ ,  $-\text{C}_{1-6}$  alkyl, aryl and heterocyclyl, where the aryl and heterocyclyl groups are optionally substituted with halo,  $\text{C}_{1-6}$  alkyl or halo substituted  $\text{C}_{1-6}$  alkyl, and the ring nitrogen of the pyridyl ring may optionally be an N-oxide.

69. (Withdrawn) The compound according to claim 67 or a salt thereof, wherein the pyridyl ring is optionally substituted with a substituent selected from halo, alkyl,  $\text{C}_6\text{H}_5-$ ,  $\text{CH}_3-\text{C}_6\text{H}_4-$ ,  $\text{CF}_3-\text{C}_6\text{H}_4-$ , pyridyl and  $-\text{NO}_2$ , and the ring nitrogen of the pyridyl ring may optionally be an N-oxide.

70. (Withdrawn) The compound according to claim 67 or a salt thereof, wherein the pyridyl ring is not substituted.


71. (Withdrawn) The compound according to claim 67 or a salt thereof, wherein  $-\text{B}-\text{C}-$  is a linker of the formula  $-\text{CH}_2\text{CH}_2-$ .

72. (Withdrawn) The compound according to claim 67 or a salt thereof, wherein X is oxygen or sulphur.

73. (Withdrawn) The compound according to claim 67 or a salt thereof, wherein X is oxygen.


74. (Withdrawn) The compound according to claim 67 or a salt thereof, wherein  $\text{R}_1$  is an optionally substituted aryl or heterocyclyl group.

75. (Withdrawn) A compound of the formula




or a salt thereof, wherein the pyridyl ring is optionally substituted and  $R_1$  and X are as defined in claim 67, with the proviso that  $R_1$  is not 4-chlorophenyl.

76. (Withdrawn) A compound of the formula




or a salt thereof, wherein the fused pyridazinyl ring is optionally substituted and  $R_1$  and X are as defined in claim 67, with the proviso that  $R_1$  is not phenyl, 4-chlorophenyl or 4-methoxyphenyl.

77. (Withdrawn) A compound of any one of the formula



and salts thereof, wherein the fused pyridyl, pyrazinyl, pyridazinyl or pyrimidinyl ring is optionally substituted and  $R_1$  and X are as defined in claim 67.

78. (Withdrawn) A method for the production of a compound of formula I according to claim 38, comprising the step of reacting a compound of formula III:



Formula III

or a salt thereof, with an acylating agent, an isocyanate or an isothiocyanate.

79. (Withdrawn) A method of separating the enantiomers of a compound of formula III, comprising forming diastereomeric salts of the compounds using an enantiomerically enriched chiral hydrogen phosphate.

80. (Withdrawn) A method of separating the enantiomers of a compound according to claim 67, comprising forming diastereomeric salts of the compound using an enantiomerically enriched chiral hydrogen phosphate.

81. (Previously Presented) The compound according to claim 38 in a substantially pure optically active form.

82. (Withdrawn) The compound according to claim 67 in a substantially pure optically active form.

83. (Withdrawn) The compound according to claim 75 in a substantially pure optically active form.

84. (Withdrawn) The compound according to claim 76 in a substantially pure optically active form.

85. (Withdrawn) The compound according to claim 77 in a substantially pure optically active form.

86. (Cancelled).

87. (New) The method of claim 1, wherein R<sub>1</sub> is optionally substituted phenyl.

88. (New) The method of claim 1, wherein R<sub>2</sub> is COR<sub>3</sub>.

89. (New) The method of claim 1, wherein  $R_1$  is optionally substituted phenyl,  $R_2$  is  $COR_3$ ,  $R_3$  is optionally substituted aryl or heterocyclyl, and  $m$  is 0.